Bariatric Surgery can Lower the Efficacy of DOACs
  • Zouheir Ibrahim Bitar
    Critical Care Unit, Ahmadi Hospital, Kuwait Oil Company, Fahaheel, Kuwait
  • Ossama Sajeh Maadarani
    Critical Care Unit, Ahmadi Hospital, Kuwait Oil Company, Fahaheel, Kuwait
  • Mohamed Jaber Mohsen
    Critical Care Unit, Ahmadi Hospital, Kuwait Oil Company, Fahaheel, Kuwait
  • Nawal Usamah Alkazemi
    rsing Department, Ahmadi Hospital, Kuwait Oil Company, Fahaheel, Kuwait

Keywords

Apixaban, bariatric surgery, thromboembolism

Abstract

A 39-year-old woman who was taking the contraceptive pill was admitted with right leg deep venous thrombosis (DVT). She was started on apixaban tablets, but after 8 days developed proximal progression of the DVT and pulmonary embolism. Her medical history later showed a history of sleeve gastrectomy. The patient responded to a vitamin K antagonist after heparin. The failure of the antithrombotic drug shed light on the efficacy and changed pharmacodynamics of direct oral anticoagulants (DOACs) after bariatric surgery in the absence of commercially available blood monitoring tests.

VIEW THE ENTIRE ARTICLE

References

  • Ponce J, Nguyen NT, Hutter M, Sudan R, Morton JM. American Society for Metabolic and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011-2014. Surg Obes Relat Dis 2015;11(6):1199–1200.
  • Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187–194.
  • Macgregor AM, Boggs L. Drug distribution in obesity and following bariatric surgery: a literature review. Obes Surg 1996;6:17–27.
  • Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51:549–561.
  • DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 2014;37:217–233.
  • Yska JP, van der Linde S, Tapper VV, Apers JA, Emous M, Totté ER, et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg 2013;23:819–825.
  • Frost C. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. Clin Pharmacol Drug Dev 2013;2(Supp 1):19 (abstract 1703161).
  • Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48:1–22.
  • Douros A, Schlemm L, Bolbrinker J, Ebinger M, Kreutz R. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. Thromb Haemost 2014;112(2):419–420.
  • Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol 2015;55(11):1286–1292.
  • Mahlmann A, Gehrisch S, Beyer-Westendorf J. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 2013;36:533–535.
  • Kröll D, Nett PC, Borbély YM, Schädelin S, Bertaggia Calderara D, Alberio L, Stirnimann G. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. Surg Obes Relat Dis 2018;14(12):1890–1896.

    • Views: 779
    HTML downloads: 130
    PDF downloads: 2233

    Published: 2020-09-30
    Issue: 2020: Vol 7 No 12 (view)

    How to cite:
    1.
    Bitar ZI, Maadarani OS, Mohsen MJ, Alkazemi NU. Bariatric Surgery can Lower the Efficacy of DOACs. EJCRIM 2020;7 doi:10.12890/2020_001954.

    Most read articles by the same author(s)